Large-scale Out-licensing Success and Global Capital Attraction of Nordic Biotechs

NLS Days (Nordic Life Science Days) 2026, held in Stockholm, Sweden, broke records with its largest-ever participation, bringing together over 230 healthcare companies and 180 global investors. The Swedish biotech ecosystem demonstrated strong commercial potential, achieving cumulative out-licensing deals totaling $2.9 billion, including $161 million in upfront payments from the previous year. Notably, Eli Lilly validated the value of Nordic technology by adopting AlzeCure Pharma's gamma-secretase modulator and BioArctic's BrainTransporter technology for crossing the blood-brain barrier. Furthermore, competition for Nordic assets among global pharmaceutical companies is intensifying, as seen in Japan's Otsuka Pharmaceutical acquiring Cantargia's immune disease program for over $600 million.

Financing Bottlenecks Hindering Late-stage Clinical Entry and Dependence on Big Pharma

While the Nordic biotech ecosystem maintains relatively stable early-stage Seed and Series A investments, it faces a severe capital cliff during Phase 3 clinical trials, which require hundreds of billions of Korean won. SwedenBIO diagnosed that most promising biotechs are forced to choose licensing partnerships with big pharma instead of independent commercialization because they cannot afford late-stage clinical costs. Despite the EU Horizon program's announcement of future budget expansions, the persistent gap in short-term development costs has made attracting global capital a key challenge for survival. This serves as a catalyst for Nordic biotechs to accelerate global licensing deals, while simultaneously acting as a structural limitation to building independent commercialization platforms.

Lytix Biopharma's Strategy for Entering Phase 3 with Oncolytic Peptide

Lytix Biopharma, a leader of the Oslo Cancer Cluster in Norway, announced plans to enter Phase 3 clinical trials for ruxotemitide, an oncolytic peptide candidate targeting malignant melanoma. This substance is designed to reactivate immune responses in patients showing resistance to the current Standard of Care, such as pembrolizumab (Keytruda) and the combination therapy of nivolumab and ipilimumab. In a preceding Phase 2 clinical trial, it demonstrated highly durable anticancer efficacy, with an Objective Response Rate (ORR) of 13.6% and a Clinical Benefit Rate (CBR) of 40.9% maintained for over two years. The mechanism of overcoming immune exhaustion via intratumoral administration and inducing a systemic anticancer response holds high commercial value in the market for patients refractory to immune checkpoint inhibitors.

Clinical Progress of Next-Generation Pipelines Based on Epigenetics and Cell Therapy

Sweden's Cereno Scientific presented Phase 2a efficacy data for its histone deacetylase (HDAC) inhibitor pipeline, being developed as a treatment for pulmonary arterial hypertension (PAH), a rare cardiovascular disease. Unlike existing standard vasodilator treatments, which have limitations in inhibiting disease progression, it has completed Orphan Drug Designation (ODD) in the US and Europe by focusing on a mechanism that reverses vascular remodeling. Additionally, Sweden's CuraCell has initiated Phase 1/2 clinical trials for CC-38, a Tumor-Infiltrating Lymphocyte (TIL) therapy targeting 'cold tumors' lacking immune response, using its CytoPLY platform technology. The Nordic bio cluster is rapidly diversifying its research areas beyond traditional small molecules into epigenetics and next-generation cell therapy modalities.